Lv4
420 积分 2024-03-11 加入
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
15小时前
待确认
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
4天前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
4天前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
27天前
已完结
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE
29天前
已完结
Mantle-Cell Lymphoma
29天前
已完结
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
1个月前
已完结
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
1个月前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
1个月前
已完结
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era
1个月前
已完结
皖公网安备34019202002308
